Open Peer Review Reports for: Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg ® ) in children with relapsed/refractory myeloid leukemia
Pre-publication versions of this article are available by contacting info@biomedcentral.com.
| Original Submission | ||
|---|---|---|
| 14 Feb 2006 | Submitted | Original manuscript |
| 1 May 2006 | Reviewed | Reviewer Report - Frederick Appelbaum |
| 6 Jun 2006 | Author responded | Author comments - Benoit Brethon |
| Resubmission - Version 2 | ||
| 6 Jun 2006 | Submitted | Manuscript version 2 |
| 13 Jun 2006 | Author responded | Author comments - Benoit Brethon |
| Resubmission - Version 3 | ||
| 13 Jun 2006 | Submitted | Manuscript version 3 |
| 16 Jun 2006 | Author responded | Author comments - Benoit Brethon |
| Resubmission - Version 4 | ||
| 16 Jun 2006 | Submitted | Manuscript version 4 |
| Publishing | ||
| 28 Jun 2006 | Editorially accepted | |
| 28 Jun 2006 | Article published | 10.1186/1471-2407-6-172 |
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.
You can find further information about the peer review system here.
